<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00210366</url>
  </required_header>
  <id_info>
    <org_study_id>IELSG21</org_study_id>
    <nct_id>NCT00210366</nct_id>
  </id_info>
  <brief_title>Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma</brief_title>
  <official_title>Salvage Therapy With Idarubicin in Immunocompetent Patients With Relapsed or Refractory Primary Central Nervous System Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Extranodal Lymphoma Study Group (IELSG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Extranodal Lymphoma Study Group (IELSG)</source>
  <brief_summary>
    <textblock>
      The main objective of the trial is to assess the therapeutic activity of idarubicin as
      salvage treatment in patients with recurrent or progressive lymphoma in the central nervous
      system.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to slow accrual
  </why_stopped>
  <start_date>November 2004</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response to treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute side effects of idarubicin</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of non-Hodgkin's lymphoma

          -  Disease exclusively localised into the CNS at first diagnosis and failure

          -  Progressive or recurrent disease

          -  Previous treatment with HDMTX containing CHT and/or RT

          -  Presence of at least one target lesion, bidimensionally measurable

          -  Age 18 - 75 years

          -  ECOG performance status &lt; 3 (Appendix 1).

          -  No known HIV disease or immunodeficiency

          -  HBsAg-negative and Ab anti-HCV-negative patients.

          -  Adequate bone marrow function (plt &gt; 100000 mm3, Hb &gt; 9 g/dl, ANC &gt; 2.000 mm3)

          -  Adequate renal function (serum creatinine &lt; 2 times UNL)

          -  Adequate hepatic function (SGOT/SGPT &lt; 3 times UNL, bilirubin and alkaline phosphatase
             &lt; 2 times UNL)

          -  Adequate cardiac function (VEF â‰¥ 50%)

          -  Absence of any psycological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule

          -  Non-pregnant and non-lactating status for female patients. Adequate contraceptive
             measures during study participation for sexually active patients of childbearing
             potential.

          -  No previous or concurrent malignancies at other sites with the exception of surgically
             cured carcinoma in-site of the cervix and basal or squamous cell carcinoma of the skin
             and of other neoplasms without evidence of disease since at least 5 years.

          -  No concurrent treatment with other experimental drugs.

          -  Informed consent signed by the patient before registration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres JM Ferreri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>San Raffaele Hospital - HSR Servizio di radiochemioterapia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Servizio Radiochemioterapia - Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.ielsg.org</url>
    <description>Click here for more information about this study</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>July 29, 2010</last_update_submitted>
  <last_update_submitted_qc>July 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>International Extranodal Lymphoma Study Group</name_title>
    <organization>IELSG</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

